SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Overview

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Cost of Revenue

Cost of Revenue analysis for BCYPU.

Quarterly Cost of Revenue

$752670.00

As of Mar 31, 2026

Annual Cost of Revenue (TTM)

$1.52M

Trailing 12 months ending Mar 31, 2026

Average Cost of Revenue (Comparison Companies)

Cost of Revenue History

Cost of Revenue Comparison

Annual Cost of Revenue Growth Rate (%)

Annual Cost of Revenue Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin